4-Trifluoromethylsalicylic acid structure
|
Common Name | 4-Trifluoromethylsalicylic acid | ||
|---|---|---|---|---|
| CAS Number | 328-90-5 | Molecular Weight | 206.119 | |
| Density | 1.5±0.1 g/cm3 | Boiling Point | 286.4±40.0 °C at 760 mmHg | |
| Molecular Formula | C8H5F3O3 | Melting Point | 178ºC | |
| MSDS | USA | Flash Point | 127.0±27.3 °C | |
Use of 4-Trifluoromethylsalicylic acid4-Trifluoromethylsalicylic acid (Desacetyl triflusal) is a platelet aggregation inhibitor[1]. |
| Name | 2-Hydroxy-4-(trifluoromethyl)benzoic acid |
|---|---|
| Synonym | More Synonyms |
| Description | 4-Trifluoromethylsalicylic acid (Desacetyl triflusal) is a platelet aggregation inhibitor[1]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 286.4±40.0 °C at 760 mmHg |
| Melting Point | 178ºC |
| Molecular Formula | C8H5F3O3 |
| Molecular Weight | 206.119 |
| Flash Point | 127.0±27.3 °C |
| Exact Mass | 206.019073 |
| PSA | 57.53000 |
| LogP | 4.16 |
| Vapour Pressure | 0.0±0.6 mmHg at 25°C |
| Index of Refraction | 1.510 |
| Hazard Codes | Xi: Irritant; |
|---|---|
| Risk Phrases | R36/37/38 |
| Safety Phrases | 26-36/37/39 |
| HS Code | 2918290000 |
| Precursor 10 | |
|---|---|
| DownStream 7 | |
| HS Code | 2918290000 |
|---|---|
| Summary | HS: 2918290000 other carboxylic acids with phenol function but without other oxygen function, their anhydrides, halides, peroxides, peroxyacids and their derivatives Tax rebate rate:9.0% Supervision conditions:AB(certificate of inspection for goods inward,certificate of inspection for goods outward) VAT:17.0% MFN tariff:6.5% General tariff:30.0% |
|
The study of the influence of surfactant charge on alkaline hydrolysis reactions of acetylsalicylic acid (ASA) and triflusal (TFL) using spectrophotometric methods.
Eur. J. Pharm. Sci. 31(3-4) , 211-20, (2007) In this research, the effects of micellar systems on alkaline hydrolysis reactions of acetylsalicylic acid (ASA) and triflusal (TFL) were found to be dependant upon the surfactant charge within the mi... |
|
|
A phase I study to characterize the multiple-dose pharmacokinetics, pharmacodynamics and safety of new enteric-coated triflusal formulations in healthy male volunteers.
Expert Opin. Drug Metab. Toxicol. 7(12) , 1471-9, (2011) An enteric-coated formulation of triflusal (triflusal EC), an antiplatelet agent, was developed to reduce the high incidence of gastrointestinal adverse events (AEs). The aim of this study is to compa... |
|
|
Salicylates increase insulin secretion in healthy obese subjects.
J. Clin. Endocrinol. Metab. 93(7) , 2523-30, (2008) Conflicting results on the effects of salicylates on glucose tolerance in subjects with normal glucose tolerance or type 2 diabetes have been reported.The objective of the study was to investigate the... |
| Benzoic acid, 2-hydroxy-4-(trifluoromethyl)- |
| QVR BQ DXFFF |
| 2-Hydroxy-4-(trifluoromethyl)benzoic acid |
| MFCD01529657 |
| 4-Trifluoromethylsalicylic acid |
| 4-Trifluoromethyl Salicylic Acid |
| 2-hydroxy-4-trifluoromethyl benzoic acid |
| Triflusal impurity B |
| 4-(TrifluoroMethyl)salicylic Acid |
| 4-Tfmsa |